Evidence map›Paper›PMID 39005546›Full record

ArticleOncoimmunology2024

Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment.

Camille Chatelain, Laurine Berland, Marion Grard, Nicolas Jouand, Judith Fresquet, Joëlle Nader, Ugo Hirigoyen, Tacien Petithomme, Chantal Combredet, Elvire Pons-Tostivint and 6 more

Abstract read
In one paragraph

Article in Oncoimmunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. The emerging role of oncolytic virotherapy in genitourinary malignancies.Frontiers in cell and developmental biology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Camille ChatelainNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.
Laurine BerlandNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.
Marion GrardNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.
Nicolas JouandLabEx IGO, Nantes Université, Nantes, France.
Judith FresquetNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.
Joëlle NaderNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.
Ugo HirigoyenNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.
Tacien PetithommeNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.
Chantal CombredetVaccines Innovation Laboratory, Institut Pasteur, Université de Paris Cité, Paris, France.
Elvire Pons-TostivintNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.
Delphine FradinNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.
Lucas TrepsNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.
Christophe BlanquartNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.
Nicolas BoisgeraultNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.
Frédéric TangyVaccines Innovation Laboratory, Institut Pasteur, Université de Paris Cité, Paris, France.
Jean-François FonteneauNantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, Nantes, France.ORCID 0000-0002-3284-8319

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Attenuated measles virus (MV) exerts its oncolytic activity in malignant pleural mesothelioma (MPM) cells that lack type-I interferon (IFN-I) production or responsiveness. However, other cells in the tumor microenvironment (TME), such as myeloid cells, possess functional antiviral pathways. In this study, we aimed to characterize the interplay between MV and the myeloid cells in human MPM. We cocultured MPM cell lines with monocytes or macrophages and infected them with MV. We analyzed the transcriptome of each cell type and studied their secretion and phenotypes by high-dimensional flow cytometry. We also measured transgene expression using an MV encoding GFP (MV-GFP). We show that MPM cells drive the differentiation of monocytes into M2-like macrophages. These macrophages inhibit GFP expression in tumor cells harboring a defect in IFN-I production and a functional signaling downstream of the IFN-I receptor, while having minimal effects on GFP expression in tumor cells with defect of responsiveness to IFN-I. Interestingly, inhibition of the IFN-I signaling by ruxolitinib restores GFP expression in tumor cells. Upon MV infection, cocultured macrophages express antiviral pro-inflammatory genes and induce the expression of IFN-stimulated genes in tumor cells. MV also increases the expression of HLA and costimulatory molecules on macrophages and their phagocytic activity. Finally, MV induces the secretion of inflammatory cytokines, especially IFN-I, and PD-L1 expression in tumor cells and macrophages. These results show that macrophages reduce viral proteins expression in some MPM cell lines through their IFN-I production and generate a pro-inflammatory interplay that may stimulate the patient's anti-tumor immune response.

Indexed as

Coculture TechniquesMacrophagesMeasles virusOncolytic VirotherapyOncolytic VirusesTumor MicroenvironmentCell DifferentiationCell Line, TumorHumansInterferon Type ILung NeoplasmsMesothelioma, MalignantMonocytesInterferon Type IMeasles virusmesotheliomaoncolytic immunotherapytumor associated macrophagestype I interferon

Identifiers

PMID39005546
PMCPMC11244337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.